Provided by Tiger Trade Technology Pte. Ltd.

Quoin Pharmaceuticals

6.12
+0.965018.72%
Post-market: 5.70-0.4200-6.86%19:59 EDT
Volume:31.02M
Turnover:228.76M
Market Cap:12.29M
PE:-0.72
High:8.25
Open:7.22
Low:5.95
Close:5.16
52wk High:41.80
52wk Low:3.25
Shares:2.01M
Float Shares:1.43M
Volume Ratio:937.86
T/O Rate:2165.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.5210
EPS(LYR):-14.7963
ROE:-575.73%
ROA:-114.60%
PB:3.13
PE(LYR):-0.41

Loading ...

NASDAQ Trade Halt Volatility Trading Pause at 09:57 Am

Reuters
·
Jun 24

Quoin Pharmaceuticals Ltd : Maxim Group Cuts Target Price to $16 From $40

THOMSON REUTERS
·
Jun 23

Quoin Pharmaceuticals' Potential Skin Disease Treatment Receives US Name Approval

MT Newswires Live
·
Jun 23

Quoin says FDA conditionally approves QYLEKI as brand name for QRX003 Netherton syndrome drug

Reuters
·
Jun 23

Quoin Pharmaceuticals Completes Establishment Of Japanese Subsidiary To Advance Commercial Readiness For Qrx003

Reuters
·
Jun 18

Quoin Pharmaceuticals establishes Japan subsidiary to support QRX003 commercialization plans

Reuters
·
Jun 18

Quoin reports positive pediatric data in Netherton Syndrome program

TIPRANKS
·
Jun 16

Quoin says QRX003 improves 4 of 6 pediatric Netherton syndrome patients in compassionate use program

Reuters
·
Jun 16

Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program

GlobeNewswire
·
Jun 16

Quoin Pharmaceuticals' Skin Disorder Drug Receives Orphan Drug Designation in Japan

MT Newswires Live
·
Jun 04

Quoin says Japan MHLW grants orphan drug status to QRX003 for Netherton syndrome

Reuters
·
Jun 04

Quoin Pharmaceuticals submits QRX003 IND application to FDA

TIPRANKS
·
Jun 02

Quoin Pharmaceuticals submits FDA IND for QRX003 in Peeling Skin Syndrome

Reuters
·
Jun 02

Quoin Pharmaceuticals (QNRX) Receives a Buy from Maxim Group

TIPRANKS
·
May 08

Quoin Pharmaceuticals Q1 EPS $(1.77) Misses $(1.72) Estimate

Benzinga Earnings
·
May 07

Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 07

Quoin Pharmaceuticals Ltd expected to post a loss of $1.93 a share - Earnings Preview

Reuters
·
May 05

Quoin Pharmaceuticals Initiated at Buy by LUCID CAPITAL MARKETS

Dow Jones
·
May 05

Quoin Pharmaceuticals initiated with a Buy at Lucid Capital

TIPRANKS
·
May 04

Quoin Pharma to report Q1 results, provide corporate update May 7

Reuters
·
Apr 30